基因多态性CYP2D6对Tramadol在膝关节关节整形术中的有效性的影响
Erdi Gürbüz1, Abdo A Elfiky2, Nusret Ök1
1Department of Orthopedics, Pamukkale University Faculty of Medicine, Denizli, Türkiye.
In vivo (Athens, Greece)
|February 27, 2026
概括
基因CYP2D6的变异会影响特拉马多尔在膝盖手术后对疼痛的作用. 基因检测可以帮助个性化疼痛管理,以获得更好的结果.
科学领域:
- 药物遗传学 药物遗传学
- 分子生物学分子生物学
- 疼痛管理 疼痛管理
背景情况:
- 特拉马多尔是手术后常见的止痛药.
- CYP2D6基因变异可能会影响药物代谢.
- 了解这种联系对于优化疼痛缓解至关重要.
研究的目的:
- 为了研究CYP2D6基因多态性和特拉马多尔疗效之间的关联.
- 根据其CYP2D6基因型,评估特拉马多尔在全膝关节整形术 (TKA) 患者的有效性.
主要方法:
- 在210名参与者 (110名TKA患者,100名对照组) 上进行了CYP2D6的基因型鉴定.
- 在接受特拉马多尔治疗的TKA患者中,使用视觉模拟量表 (VAS) 测量疼痛强度.
- 统计分析比较了基因型-表型分布和VAS得分.
主要成果:
- 广泛代谢器 (EM) 现型是最常见的 (78.2%).
- CYP2D6*3和*4等位基因与VAS得分的变化相关.
- 在EM患者中,特拉马多尔的疼痛缓解效果比中间代谢剂更好.
结论:
- CYP2D6基因型显著影响特拉马多尔的疗效和潜在的副作用.
- 建议对CYP2D6进行药物遗传测试,以指导术后疼痛管理策略.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
51
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
51
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
79
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
79

